Background: Specific mutations in VPR and V2 potentially restrict HIV-1 replication in macrophages. Such restriction could potentially limit HIV replication in long-term non-progressors (LTNP), thus accounting for low viral load and delayed progression to AIDS.
Introduction
Human immunodeficiency virus type 1 (HIV-1) infection and its associated disease represent a dynamic and long-lasting struggle between the virus and the immune system of the infected host [1, 2] . Progression of HIV-1 infection is generally dependent on high viral loads and the lack of efficiency of the host immune response to control viremia [2, 3] . In addition, viral factors such as mutations in the external glycoprotein, insertion/deletions in the regulatory genes, coreceptor utilization of primary HIV-1 as well as alleleic polymorphism in coreceptor genes have all been associated with disease progression or non-progression [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Thus, a multitude of viral, genetic, and host factors appear to impact HIV-1 disease progression.
The regulatory and accessory genes of HIV play major roles in both virus expression, and in the activation process of the cell [16] . The vpr gene product is produced late in the virus life cycle and assembled into the virion through binding to gag. The incorporation of VPR into the viral particle provides both a mechanism for delivery of VPR protein into cells at the time of infection as well as a means of exporting VPR from infected cells [16] [17] [18] [19] [20] . Although VPR is not required for virus replication in T-cells, it plays a major role in viral replication in macrophages [18] . Furthermore, continuous passage of HIV in culture gives rise to specific vpr mutations, indicating that vpr mutations may be necessary for the establishment of chronic infection [17, 20, 21] . Thus, chronic HIV-1 infection and disease progression may also be influenced by a specific VPR phenotype (truncated versus non-truncated).
The principal determinants of viral fusion, coreceptor usage, and neutralization of HIV-1 are found in the V1-V3 region of the envelope [4, [22] [23] [24] [25] . The crystal structure of gp120 has led to a better understanding of viral binding steps and has elucidated the role of V1V2 in this interaction [4, 26] . These studies have established that the gp120 core is composed of an inner domain, an outer domain, and a 'bridging sheet,' including a V1V2 stem [27] . The V1V2 stem and fourth conserved region make up the CD4-induced epitope. CD4 binding to gp120 distorts the V1V2 loop; this is followed by repositioning of the bridging sheet, which allows for CCR5 binding [4, 27] . The mutations in the V1V2 stem combined with V3 mutations might affect the formation of this bridging sheet, allowing this mutant to interact with CCR5 differently after CD4 binding. Additionally, altered glycosylation and mutations in the V2 loop protect the virus from neutralization and expand cellular tropism by allowing the virus to replicate more efficiently in primary macrophages [28] [29] [30] [31] [32] [33] [34] . Taken together, the V1V2 region appears to be a critical determinant for viral entry, replication, and disease pathogenesis. Among many factors associated with HIV-1 disease progression and non-progression, a phenotypic switch from CCR5 to CXCR4 has been associated with rapid disease progression [35] [36] [37] [38] [39] [40] . As alterations in the V2 region and vpr have been shown to be critical for coreceptor interaction as well as for macrophage replication [17, 20, 23, 34] , we sought to determine the role of V1V2 and vpr in viral replication and disease progression in a cohort of homosexual men followed since the early part of the HIV-1 epidemic. In the present study we asked whether (1) a specific VPR phenotype (truncated versus non-truncated) correlates with disease progression; (2) elongated V2 restricts viral replication in macrophages; and (3) specific mutations or elongation in V1V2 alter viral tropism and coreceptor interaction. Although some studies have shown that V1V2 elongation does not restrict macrophage replication, we provide evidence for a relationship between an acquisition of elongated V2 and maintenance of CCR5 tropism among HIV-1 infected persons who do not develop AIDS.
Materials and methods

Study participants
The individuals chosen for the study were part of a cohort of HIV-1-seropositive homosexual men (dates of acquisition of HIV infection unknown) followed since 1982-1983 by researchers at the Centers for Diseases Control and Prevention (CDC) in Atlanta, Georgia [41] . The study participants were categorized as rapid progressors (RPs), late progressors (LPs), or long-term non-progressors (LTNPs) based on their CD4 counts and time to AIDS development. Rapid progressors (n ¼ 4) were defined as individuals who had AIDS-defining symptoms and whose CD4 counts fell below 200 3 10 6 cells/l within 5 years of entry into the study. Late progressors (n ¼ 6) were individuals who developed AIDS more slowly, with a gradual decline in CD4+ T-cell counts to , 400 3 10 6 cells/l after 5 years of observation. Long-term non-progressors (n ¼ 3) were individuals whose CD4 counts have been . 400 3 10 6 cells/l for more than 7-12 years after study entry and who have had no symptoms of HIVrelated disease [37] . Specimens were tested at many time points during the progressive or non-progressive phase of HIV infection, as indicated in the Results section.
Additional LTNPs were selected from an epidemiologically linked cohort and a mother-child pair from Australia. First, a look-back analysis of the Australian Red Cross Blood Service registry at the Sydney Blood Bank (SBCC-III) identified four persons who acquired HIV-1 by blood transfusion between 1984 and 1985 from a common donor; all have remained LTNPs for more than 14 years. Second, we selected a LTNP mother-child pair both of whom have been infected since 1983. Although the exact infection date for the mother remains unknown, she infected her child via breast-feeding in 1983; both mother and child have survived without symptoms. Samples from both of these LTNP categories were collected in 1999.
VPR analysis
A polymerase chain reaction (PCR)-based assay was used to test for a specific non-sense mutation as previously described [21] . Constitutive HIV-1 expressing T-cell lines ( 8E5/LAV, CR10/N1T) or promyeloytic cell line (PLB/IIIB), and latently infected T-cell line (ACH2) and promyelocytic line (OM10.1/LAV) were analysed for VPR mutations [42] . Subsequent analysis was carried out using DNA from primary lymphocytes or virus isolated from the RPs, LPs, and LTNPs.
The complete VPR sequences were amplified from selected RP and LTNP isolates using a nested PCR. The outer set of primers consisted of MO46 forward 59-ATGGAACAAGCCCCAGAA and MO45 reverse 59-CTAGGATCTACTGGCTCC. The inner set of primers were MO51 forward 59-TGGGGTCTGCA TACAGGAGA and MO100 reverse 59-CTTCCTG CCATAGGAGATGC. The PCR reactions were carried out with MgCl 2 at 2 mmol/l and primers at 25 mmol/l final concentration. The PCR conditions were 35 cycles of 30 s at 948C, 30 s at 558C, and 1 min at 728C each, followed by a final extension step for 5 min at 728C for both the first and second round.
Analysis of V1V2 region
Two hundred microlitres of DNA was purified from infected peripheral blood mononuclear cells (PBMCs) by using the QIAmp DNA blood mini kit (Qiagen, Valencia, California, USA). RNA from viral stocks or culture supernatants was obtained using the QIAamp viral RNA mini kit (Qiagen). Sequential DNA lysates and viral RNA were amplified in the V1V2 and C2V3 region using a set of primers and concentrations previously described [43] . Briefly, conditions for the first-round amplification were as follows: 3 min at 948C, 1 min at 538C, and 2 min at 728C for one cycle, followed by 25 cycles of 1 min at 948C, 30 s at 538C, and 2 min at 728C each. For the nested reaction 35 cycles of 1 min at 948C, 30 s at 538C, and 2 min at 728C each were used. The final extension was carried out at 728C for 7 min. The amplified material was purified using the QIAquick PCR purification kit (Qiagen). The PCR amplification products were visualized on 1.2% agarose gel stained with ethidium bromide.
For selected patients, characterization of quasispecies was determined by cloning of the V1V2 amplified material. The amplified products were cloned into a pCR-TOPO plasmid using the manufacturer's protocol (Invitrogen, Carlsbad, California, USA), and at least 12 white colonies were picked for each time point. Purified PCR products were sequenced using Big-dye Terminator technology (Applied Biosystems, Foster City, California, USA). Sequencing reactions were run on a 377 sequencer (Applied Biosystems). Sequences were edited and aligned using the Vector NTI suite (InforMax, Inc., Bethesda, MD, USA).
Virus isolation and infection studies
All viral isolates were established by cocultivation of patient PBMCs with PHA-stimulated uninfected donor PBMCs. Culture supernatants were collected, filtered through 0.22 ìm filters, tested for reverse transcriptase (RT) activity, aliquoted, and stored at À708C. Cellculture-adapted-T-tropic (LAI) and M-tropic (BAL) laboratory isolates of HIV-1 were used as controls. Forty-one sequential HIV-1 isolates were obtained from the four RPs, six LPs and three LTNPs in the cohort of homosexual men, as described previously [37] . All plasma specimens, DNA lysates and viral stocks were stored at -708C, whereas human PBMCs were stored in liquid nitrogen.
Human PBMC and monocyte-derived macrophage and GHOST infections CD8-depleted, PHA-stimulated PBMC were infected with sequential HIV-1 viral isolates at 40 000 RT counts per 1 3 10 6 cells [37] . After 3 h of incubation with the virus, cells were washed three times with phosphate-buffered saline and cultures were maintained in RPMI supplemented with 10% fetal calf serum, 10% interleukin (IL)-2, streptomycin (100 mg/ml), penicillin (100 units/ml), and glutamine (2 mmol/l) (C-RPMI). Supernatants were collected every 3 days from the cultures for 14 days and tested for p24 antigen production (Coulter, Hialeah, Florida, USA). For the monocyte-derived macrophage (MDM) infections, monocytes were resuspended in Dulbecco's Modified Eagle Medium supplemented with gentamicin (0.02 mg/ml), glutamine (2 mmol/l), and GM-CSF (1000U/ml) and plated at 1 3 10 6 cells in 96-well plates, and infections were carried out as described previously [43] . After 5-7 days in culture at 378C, cells from two different donors were infected with 40 000 RT counts of the viral stock from primary isolates, or laboratory-adapted BAL. After 2 h of incubation, the cells were washed with media and the cultures were monitored for cytopathic effect (CPE) for 14 days. Culture supernatants were also collected every 2 days and tested for p24 antigen production (Beckman-Coulter, Miami, FL, USA). The GHOST4 cell infection were carried out essentially as described previously [37] .
Cytokine and chemokine induction
Levels of TNF-AE, IFNª, IL-10 (Biosource International, Camarillo, California, USA), and MIP-1â (R&D Systems, Minneapolis, Minnesota, USA) in culture supernatants were determined by commercial immunoassays following manufacturer's protocols. The Student's t-test was used to determine significant differences between the groups.
Results
Truncated VPR associated with chronic HIV infection Previous studies have established that mutations in VPR correlate with differential replication capacity in macrophages and T-cells [17, 20, 21] . Specifically, a stop codon at position 77 was shown to be critical for chronic infection of T cells [21] . This specific mutation was also shown to be a characteristic of viral species that survive initial cytopathicity in vitro [17] . To better understand the relationship of truncated VPR to chronic infection of T-cells, we tested several T-cell lines that harbor either chronic or latent HIV-1 [42] . Analysis of cell lines using a PCR-based assay with specific primers that amplify both the wild-type or mutant form of VPR demonstrated that all three chronic infected lines (8E5, CR10 and PLB) had the truncated form, whereas the latent lines (ACH-2 and OM10.1) contained the non-truncated type ( Fig. 1 ). Induction of HIV-1 replication from these latent lines by exposure to TNF-AE resulted in a marked increase in p24 production (data not shown); however, there was no difference in the VPR phenotype ( Fig. 1 ). As expected, all laboratory viral stocks tested contained the wild-type VPR (data not shown). These data suggest that VPR truncation allows for continued viral replication in T-cells and might be associated with constitutive viral production in vivo.
We next tested for the presence or absence of this stop codon at position 77 using PCR on primary PBMCs from RPs and LTNPs. None of the RP or LTNP PBMCs revealed the presence of this stop codon that would result in a truncated VPR protein (data not shown). To further explore other potential mutations in VPR that would impact macrophage replication efficiency and disease progression, full-length sequencing was carried out on sequential specimens from RPs and LTNPs. Analysis of specimens from four RPs and two LTNPs did not reveal a stop codon that would truncate the VPR or any other mutation that would correlate with disease progression (Fig. 2 ). Furthermore, we did not find the R77Q mutation, which has previously been shown to be present among LTNPs [11, 14] .
Sequence analysis of V1-V3 env region
To establish a relationship between the genetic diversity of V1-V3 and HIV-1 disease progression, sequential isolates from RPs, LPs and LTNPs were sequenced in the V1V2 region. Analysis of the V1 region revealed extensive length polymorphism regardless of disease status. Analysis of RPs showed that the V1 loop could be as short as 16 amino acids or as long as 37 amino acids. Isolates from three of the four RPs showed a shorter V1 over time with a significant loss of 21 amino acids for one RP (Table 1) . A similar analysis of isolates from the six LP showed that the V1 length varies between 24-39 amino acids and that five of the six LPs had a longer V1 loop over time (up to 12 amino acids long). Likewise, the V1 lengths for the three LTNPs were 22-31 amino acids long, with two of them having acquired up to 5 amino acids over time. Furthermore, there was no correlation between acquisition or loss of glycosylation sites in V1 and disease progression.
In contrast, we observed a marked difference in acquisition of V2 length and disease progression. Analysis of the V2 region revealed that all RPs maintained a 39 amino acid length, while most LPs and LTNPs acquired 1 to 13 amino acids over time, and the V2 length varied between 38-49 amino acids.
( Table 1 ). The elongation was consistently observed at the second glycosylation site of the V2 loop (aa 185 HXB2) (data not shown). In some cases, elongation in the V2 region resulted in additional glycosylation sites; however, no clear association between the number of glycosylation sites and disease status was observed. Further analysis of the C2V3 region did not reveal any other striking differences that correlated with acquisition of an elongated V2 (Table 1 ). These results indicate that the acquisition of an extended V2 may be associated with a delay in disease progression.
Replication kinetics of primary isolates in human macrophage and PBMCs
A previous study demonstrated that recombinant virus with extended V2 replicated poorly in macrophages [34] . We, therefore, hypothesized that acquisition of an elongated V2 may correlate with poor replication in macrophages, thereby accounting for low viremia. Infection of human monocyte-derived macrophages and PBMCs were carried out using sequential primary isolates derived from patients with varying lengths of V2. All isolates derived from RPs (RP5084, RP5108 and RP5157; with no change in V2 length) replicated well both in macrophages ( Fig. 3 ) and in PBMCs (data not shown), although some variability in replication was observed among sequential isolates. Longitudinal isolates from LPs (LP5160, LP5077, LP5127), as well as from LTNPs (LTNP5096 and LTNP5155) ( Fig. 3 ) that had acquired elongation in V2, showed no difference in replication in macrophages regardless of short (filled line) or long V2 (dotted line). Results from a representative experiment are shown in Figure 3 . Macrophage infection with viral isolates from RPs, LPs and LTNPs show the same characteristic cytopathic effect, regardless of V2 length (data not shown). Analysis of cytokine induction in culture supernatants did not reveal any difference in production of TNFAE, IL-10, IFN-ª, or MIP-1â between RPs, LPs and LTNPs from either macrophage or PBMC cultures (data not shown). Collectively, these data suggest that among LTNPs and LPs acquisition of an elongated V2 over time has no impact on replication efficiency of HIV-1 in macrophages.
In vitro viral selection does not impact macrophage infectivity
To further confirm that no selection bias of quasispecies had taken place during macrophage infection, RT-PCR analysis was carried out on MDM culture supernatants ( Fig. 4) . Comparisons of sequences from PBMC-and MDM-derived viruses from RPs (no change in V2) and LTNPs (acquisition of elongated V2) at two different time points revealed that no selection of quasispecies occurred during macrophage infection. Comparative sequence analysis revealed no difference in V2 length, and consistent sequences were observed in virus input and output (Fig. 4 ). 
Correlation betweenV2 extension and coreceptor usage
HIV-1 disease progression has previously been shown to be associated with viral adaptation to use multiple coreceptors, whereas LTNPs maintain exclusive usage of R5 over time [36] [37] [38] . As elongation in the V2 was acquired over time during the non-progressive phase of HIV-1 infection, we next examined the relationship between V2 extension and coreceptor usage ( Fig. 5 ). As expected, coreceptor switch was associated with acquisition of basic amino acids at positions 11 and 25 of V3 loop (except patient LP5048). For the most part, patients who had switched from R5 to R5X4 usage did not acquire an elongated V2 (with the exception of patient 5048), whereas those who maintained R5 usage did acquire an elongated V2 (with the exception of patient LP5148) ( Table 1) . Thus, there appears to be a trend between acquisition of V2 elongation and maintenance of R5 usage (Fig. 5) .
These observations were further substantiated in an additional six LTNP, including four members of Sydney Blood Bank donors who acquired their infection in 1984-85 from a single source (SBBC III), and in a mother-child pair. Analysis of the V2 region from four members of SBBCIII (C24, C42, C76, and C92) and mother-child pair (1181 mother, 1182 child) revealed an elongated V2 with an extension of 2 to 6 amino acids (Fig. 6a) . Interestingly, despite a common source infection among the four SBCC members and the mother-child pair, all had a different sequence in this region. Coreceptor analysis of viral isolates derived from all six members revealed that all six viral isolates use CCR5 as primary coreceptor, and do not utilize any of the other known coreceptors including CCR1, CCR2, CCR3, CCR4, CXCR4, gpr-15 and STRL-33 (Fig. 6b) . Thus, extended V2 seems to correlate with maintenance of CCR5 usage among these sets of LTNPs.
Discussion
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ies suggest that an acquisition of amino acids in the V2 region by HIV-1 strains may prevent the emergence of CXCR4 viruses resulting in long-term survival.
The role of VPR in HIV infection and pathogenesis has been suggested by a number of in vitro and in vivo studies [16] [17] [18] . Analysis of HIV-1-infected T-cell lines revealed that latent HIV-1 infection was associated with an intact VPR, whereas viruses that replicate chronically in T-cell lines have a truncated form of VPR, suggesting that VPR has a role in preventing the establishment of cell cultures that chronically produce virus. These data are in agreement with a previous report in which the ability of HIV-1-infected cell culture to survive the acute infection and establish a cell line with chronic HIV-1 infection is mediated by truncated VPR [17] . A search for truncated VPR in vivo among RPs, LPs, or LTNPs did not reveal any stop codons in VPR, suggesting that persistent low viremia among LTNPs was not due to infection of Tcells with a virus containing a truncated VPR. Some point mutations in the VPR protein were observed; however, no specific pattern was evident among RPs or LTNPs. Previous studies have reported point mutations in VPR [11] [12] [13] [14] 21] , with no consistent pattern relating to the disease progression.
Analysis of hypervariable V1 region did not reveal any specific pattern associated with disease progression or non-progression. Previous cross-sectional analysis of HIV-1 strains derived from LPs and LTNPs has revealed the presence of elongated V2 among LTNPs [34, 43] . It was suggested that the biological relevance of the V2 region might lie in impairing the viral replication in primary macrophages [34] . Analysis of sequential isolates revealed the acquisition of 2-13 amino acids in the V2 region from most LTNPs and half of the LPs. Infection of primary macrophages with viral isolates with or without extended V2 from these RPs and LTNPs revealed no difference in replication efficiency or cytopathicity in macrophages. These data are in contrast to results from the study reported by Shioda et al. [34] , which showed infection of macrophages with an infectious clone carrying an elongated V2 result in slow replication in macrophages. In addition, analysis of V2 sequences before and after infection of macrophages revealed no difference in sequences, suggesting that there was no quasi-species selection during the infection of macrophages. Since our studies were carried out with primary isolates, it is likely that parts of the HIV-1 genome, other than long V2, may have compensated for the restriction to grow in macrophages.
The data from this study provide an interesting relationship between V1V2 mutations and coreceptor utilization of primary isolates derived from RPs and LTNPs. Although most RPs adapted to usage of CXCR4 and maintained short V2 as disease progressed, most LTNPs acquired an elongated V2 while maintaining CCR5 usage. These data suggest that the envelope protein of LTNPs may interact differently with CD4 or CCR5 and that the V1/V2 loops are critical to this interaction. Conflicting reports have been published with regard to V2 length polymorphism, as well as positively charged amino acid within the V2 region and viral phenotypes [22] [23] [24] [45] [46] [47] . Viruses with syncytium-inducing phenotype (CXCR4-tropic) were reported to have V2 regions with increased length and charge [23, 45] , as compared to non-syncytium viruses (CCR5-tropic); however, other reports have failed to confirm this association [22, 24] . The data presented here provide evidence that acquisition of elongated V2 correlates with maintenance of CCR5 tropism (NSI phenotype). A possible explanation for the difference in our results and those of a recently published study may relate to the dynamics of viral evolution in a longitudinal, untreated cohort, whereas other studies have focused on cross sectional analysis [23, 45] . The availability of a detailed crystal structure of the HIV-1 envelope, provides clear evidence that the V1V2 loops are involved in virus-cell interactions and play a significant role in cellular tropism [26, 27, 48] . It is postulated that CD4 binding induces conformational changes in the V1/V2 stem-loop structure that exposes the coreceptor binding site [26, 27, 46] . Some of these conformational changes allow high-affinity interaction with CCR5 [46, 49, 50] . Although the exact mechanism of CXCR4 binding has not been elucidated, many of the residues involved in CCR5 binding appear to be involved in CXCR4 binding [27, 49] . Data presented here provide evidence that most of the RPs and half of LPs in this cohort acquired the ability to use CXCR4. There are two possible scenarios that can explain the switch in coreceptor use. First, specific changes in the envelope that lead to decreased CCR5 binding may favour adaptation to CXCR4 usage. Indeed, previous studies have shown that a substitution of aspartic acid to threonine at position 123, which is located in the V1V2 stem and contacts CD4, significantly decreases CCR5 binding [46, 47] . However, none of the RPs developed this mutation. Second, it is possible that positively charged residues in the V3 loop among RPs (a) Fig. 6 . (a) Env V2 region sequences derived from a long-term non-progressing epidemiologically linked mother (1181) and child (1182) pair and four slowly progressing members (C24, C42, C76 and C92) of the Sydney Blood Bank cohort III who acquired virus from a common source. All six reveal the presence of an extended V2 region. (b) Coreceptor usage of primary isolates derived from long-term non-progressing epidemiologically linked mother (1181) and child (1182) pair and four slowly progressing members of Sydney blood Bank cohort (C24, C42, C76 and C92). GHOST cells coexpressing CCR1, CCR2, CCR3, CCR4, CCR5, CXCR4, gpr15 and STRL-33 were infected with primary isolates and infections were followed up to 14 days postinfection. Data shown is p24 antigen production in culture supernatant for each cell line. All isolates reveal exclusive usage of CCR5. CCR1  CCR2  CCR3  CCR4  CCR5  CXCR4  gpr15  STRL 33  Parental  CCR1  CCR2  CCR3  CCR4  CCR5  CXCR4  gpr15  STRL 33  Parental   CCR1  CCR2  CCR3  CCR4  CCR5  CXCR4  gpr15  STRL 33  Parental   CCR1  CCR2  CCR3  CCR4  CCR5  CXCR4  gpr15  STRL 33  Parental   CCR1  CCR2  CCR3  CCR4  CCR5  CXCR4  gpr15  STRL 33  Parental  CCR1  CCR2  CCR3  CCR4  CCR5  CXCR4  gpr15  STRL preferentially bind negatively charged residues in CXCR4, following CD4 binding induced conformational changes that move the V1V2 loop away from the bridging sheet and result in viral entry. Thus, the acquisition of positively charged residues in the V3 loop may have accounted for the acquisition of dual tropism. The positive charge residues in the V3 loop are associated with phenotypic and coreceptor switch [22, 51] .
The most significant finding of this study relates to acquisition of an elongated V2 and its relationship to maintenance of CCR5 usage during the non-progressive phase of HIV disease. Specifically, it is likely that an elongated V2 may prevent emergence of viral variants capable of using CXCR4. Although the precise mechanism of such an interaction is not yet clear, several hypotheses can be postulated. First, CD4 binding to the envelope with an elongated V2 may create a stronger and more stable conformation with preferential affinity for gp120-CCR5 complex. Such highaffinity coreceptor interaction, together with a lack of positive charge on the V3 loops of LTNPs may prevent an interaction with CXCR4. Second, an elongated V2 may alter the bridging sheet in such a way that it cannot bind CXCR4, or completely shields the binding sites that are necessary for binding to CXCR4. Regardless of the mechanism, an elongated V2 and maintenance of CCR5-tropism in the absence of CXCR4 adaptation appears to be strongly associated with non-progressive HIV-1 disease. A better understanding of these interactions may provide insight into HIV disease progression and effective therapeutic strategies for HIV control.
